Head to Head Review: Quince Therapeutics (NASDAQ:QNCX) versus Humacyte (NASDAQ:HUMA)

Quince Therapeutics (NASDAQ:QNCX) and Humacyte (NASDAQ:HUMA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, profitability, risk, earnings and institutional ownership.

Earnings and Valuation

This table compares Quince Therapeutics and Humacyte’s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quince Therapeutics	N/A	N/A	-$31.39 million	($0.84)	-1.18
Humacyte	$1.57 million	333.74	-$110.78 million	($1.07)	-4.11

Quince Therapeutics has higher earnings, but lower revenue than Humacyte. Humacyte is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Quince Therapeutics has a beta of 1.25, meaning that its stock price is 25% more volatile than the S&P 500. Comparatively, Humacyte has a beta of 1.46, meaning that its stock price is 46% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations for Quince Therapeutics and Humacyte, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quince Therapeutics	0	0	0	0	N/A
Humacyte	0	1	3	0	2.75

Humacyte has a consensus price target of $8.00, indicating a potential upside of 81.82%. Given Humacyte’s higher possible upside, analysts plainly believe Humacyte is more favorable than Quince Therapeutics.

Institutional and Insider Ownership

30.8% of Quince Therapeutics shares are held by institutional investors. Comparatively, 44.7% of Humacyte shares are held by institutional investors. 27.9% of Quince Therapeutics shares are held by insiders. Comparatively, 23.1% of Humacyte shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Quince Therapeutics and Humacyte’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Quince Therapeutics	N/A	-36.36%	-28.83%
Humacyte	N/A	-199.62%	-61.45%

Summary

Quince Therapeutics beats Humacyte on 6 of the 11 factors compared between the two stocks.

About Quince Therapeutics

Quince Therapeutics, Inc., a preclinical stage biopharmaceutical company, develops precision therapeutics for debilitating and rare diseases. Its lead compound is NOV004, a systemically administered bone anabolic peptide engineered to target and concentrate at bone fracture sites. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.

About Humacyte

Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.